Associations between Multimorbidity and the Risks of Cardiovascular Disease Events and All-Cause Mortality in Patients with Chronic Kidney Disease.

IF 3.2 3区 医学 Q1 UROLOGY & NEPHROLOGY American Journal of Nephrology Pub Date : 2025-01-01 Epub Date: 2025-03-13 DOI:10.1159/000544722
Shigeru Tanaka, Kazuhiro Okamura, Shigeru Tanaka, Hiromasa Kitamura, Tatsuya Suenaga, Kazuhiko Tsuruya, Takanari Kitazono, Toshiaki Nakano
{"title":"Associations between Multimorbidity and the Risks of Cardiovascular Disease Events and All-Cause Mortality in Patients with Chronic Kidney Disease.","authors":"Shigeru Tanaka, Kazuhiro Okamura, Shigeru Tanaka, Hiromasa Kitamura, Tatsuya Suenaga, Kazuhiko Tsuruya, Takanari Kitazono, Toshiaki Nakano","doi":"10.1159/000544722","DOIUrl":null,"url":null,"abstract":"<p><strong>Introduction: </strong>Multimorbidity, defined as the presence of two or more chronic conditions, is associated with poor outcomes and increased cardiovascular risk in the general population. However, the effect of multimorbidity on patients with chronic kidney disease (CKD), a group of patients already at high risk for cardiovascular disease, is not well understood.</p><p><strong>Methods: </strong>We analyzed data from 4,420 patients with non-dialysis CKD enrolled in the Fukuoka Kidney disease Registry Study. We identified 23 comorbidities, including cardiometabolic and non-cardiometabolic conditions. The patients were categorized into four groups according to the number of comorbidities: Group 1 (0-1 comorbidities), Group 2 (2 comorbidities), Group 3 (3 comorbidities), and Group 4 (≥4 comorbidities). We examined the associations between the number of comorbidities and the incidence of major adverse cardiovascular events (MACE) and all-cause mortality using Cox proportional hazards models.</p><p><strong>Results: </strong>Over a 5-year follow-up, 229 patients experienced MACE and 456 died. The risk of MACE increased with the number of comorbidities. The multivariable-adjusted hazard ratios (95% confidence intervals) for MACE were 1.40 (0.80-2.44) for Group 2, 2.27 (1.33-3.88) for Group 3, and 3.53 (2.11-5.91) for Group 4 compared with Group 1. The all-cause mortality risk also increased with the number of comorbidities, with adjusted hazard ratios of 1.13 (0.77-1.66), 1.75 (1.22-2.51), and 2.53 (1.80-3.54) for Groups 2, 3, and 4, respectively.</p><p><strong>Conclusion: </strong>In patients with CKD, multimorbidity is associated with an increased risk of MACE and all-cause mortality.</p>","PeriodicalId":7570,"journal":{"name":"American Journal of Nephrology","volume":" ","pages":"605-617"},"PeriodicalIF":3.2000,"publicationDate":"2025-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"American Journal of Nephrology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1159/000544722","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/3/13 0:00:00","PubModel":"Epub","JCR":"Q1","JCRName":"UROLOGY & NEPHROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Introduction: Multimorbidity, defined as the presence of two or more chronic conditions, is associated with poor outcomes and increased cardiovascular risk in the general population. However, the effect of multimorbidity on patients with chronic kidney disease (CKD), a group of patients already at high risk for cardiovascular disease, is not well understood.

Methods: We analyzed data from 4,420 patients with non-dialysis CKD enrolled in the Fukuoka Kidney disease Registry Study. We identified 23 comorbidities, including cardiometabolic and non-cardiometabolic conditions. The patients were categorized into four groups according to the number of comorbidities: Group 1 (0-1 comorbidities), Group 2 (2 comorbidities), Group 3 (3 comorbidities), and Group 4 (≥4 comorbidities). We examined the associations between the number of comorbidities and the incidence of major adverse cardiovascular events (MACE) and all-cause mortality using Cox proportional hazards models.

Results: Over a 5-year follow-up, 229 patients experienced MACE and 456 died. The risk of MACE increased with the number of comorbidities. The multivariable-adjusted hazard ratios (95% confidence intervals) for MACE were 1.40 (0.80-2.44) for Group 2, 2.27 (1.33-3.88) for Group 3, and 3.53 (2.11-5.91) for Group 4 compared with Group 1. The all-cause mortality risk also increased with the number of comorbidities, with adjusted hazard ratios of 1.13 (0.77-1.66), 1.75 (1.22-2.51), and 2.53 (1.80-3.54) for Groups 2, 3, and 4, respectively.

Conclusion: In patients with CKD, multimorbidity is associated with an increased risk of MACE and all-cause mortality.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
慢性肾病患者多发病与心血管疾病事件和全因死亡率之间的关系
背景与假设:多病,定义为存在两种或两种以上的慢性疾病,与一般人群的不良预后和心血管风险增加有关。然而,多重发病对慢性肾病(CKD)患者(一组已经处于心血管疾病高风险的患者)的影响尚不清楚。方法:我们分析了福冈肾脏疾病登记研究中4420例非透析性CKD患者的数据。我们确定了23种合并症,包括心脏代谢和非心脏代谢疾病。根据合并症的数量将患者分为4组:1组(0-1例合并症)、2组(2例合并症)、3组(3例合并症)、4组(≥4例合并症)。我们使用Cox比例风险模型检查了合并症数量与主要不良心血管事件(MACE)发生率和全因死亡率之间的关系。结果:在5年的随访中,229例患者经历了MACE, 456例死亡。MACE的风险随着合并症数量的增加而增加。与第1组相比,第2组MACE的多变量校正风险比(95%置信区间)为1.40(0.80-2.44),第3组为2.27(1.33-3.88),第4组为3.53(2.11-5.91)。全因死亡风险也随着合并症数量的增加而增加,2组、3组和4组的校正危险比分别为1.13(0.77-1.66)、1.75(1.22-2.51)和2.53(1.80-3.54)。结论:在CKD患者中,多病与MACE和全因死亡率的风险增加有关。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
American Journal of Nephrology
American Journal of Nephrology 医学-泌尿学与肾脏学
CiteScore
7.50
自引率
2.40%
发文量
74
审稿时长
4-8 weeks
期刊介绍: The ''American Journal of Nephrology'' is a peer-reviewed journal that focuses on timely topics in both basic science and clinical research. Papers are divided into several sections, including:
期刊最新文献
When KDIGO Meets Frailty: Rethinking CKD Targets in Adults Aged 80 Years and Older. HIF-1α Drives Cellular Senescence Via Autophagy Activation to Promote AKI-to-CKD Transition. Proenkephalin for Cardiovascular and All-Cause Mortality: the REasons for Geographic and Racial Differences in Stroke Study (REGARDS) Study. Associations of calciprotein particle maturation time with echocardiographic measures in the CRIC Study. The Efficacy and Safety of Enarodustat for the Treatment of Anemia in Hemodialysis Dependent Chronic Kidney Disease Patients: A Phase 3, Multicenter, Randomized, Active-Comparator (recombinant human erythropoietin), Open-Label Study:the ENARODIAL study.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1